Literature DB >> 7903921

The role of methotrexate in the management of steroid-dependent asthma.

M J Coffey1, G Sanders, W L Eschenbacher, A Tsien, S Ramesh, R W Weber, G B Toews, W J McCune.   

Abstract

Severe asthma often requires high-dose corticosteroid therapy. However, steroid therapy is fraught with many side effects. There are conflicting reports in the literature regarding the role of methotrexate in reducing the steroid requirements of these patients. This study examined the role of low-dose methotrexate in the management of steroid-dependent asthma. Eleven subjects with stable steroid-dependent asthma were enrolled in a placebo-controlled double-blind crossover trial. Patients received methotrexate, 15 mg/wk, or placebo each for two 12-week periods. There was significant improvement of pulmonary function and reduction of prednisone requirement in both placebo and methotrexate treatment periods. However, methotrexate was not superior to placebo. Only 3 of 11 patients responded to methotrexate. Although low-dose methotrexate therapy may have a role in a small select group of steroid-dependent asthmatics, it provided no additional benefit overall.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7903921     DOI: 10.1378/chest.105.1.117

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

Review 1.  A risk-benefit assessment of methotrexate in corticosteroid-dependent asthma.

Authors:  T R Shulimzon; R J Shiner
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 2.  Asthma that is unresponsive to usual care.

Authors:  Kenneth R Chapman; Andrew McIvor
Journal:  CMAJ       Date:  2009-10-13       Impact factor: 8.262

3.  Short term effect of methotrexate in severe steroid-dependent asthma.

Authors:  G Kanzow; D Nowak; H Magnussen
Journal:  Lung       Date:  1995       Impact factor: 2.584

4.  Controlled trial of methotrexate in patients with severe chronic asthma.

Authors:  J Hedman; P Seideman; F Albertioni; B Stenius-Aarniala
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 5.  Corticosteroid-induced bone loss. Prevention and management.

Authors:  C Picado; M Luengo
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

Review 6.  Outpatient treatment of adult asthma.

Authors:  E C Kleerup; D P Tashkin
Journal:  West J Med       Date:  1995-07

7.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

8.  Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype.

Authors:  Malene Knarborg; Ole Hilberg; Hans-Jürgen Hoffmann; Ronald Dahl
Journal:  Eur Clin Respir J       Date:  2014-11-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.